Cystic Fibrosis

Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis


Introduction: Burkholderia cepacia infection has been associated with a poor prognosis for patients with cystic fibrosis (CF). It is now recognised that organisms classified as B cepacia comprise a number of distinct genomic species each known as a genomovar of the B cepacia complex (BCC). The outcome of infection for CF patients with individual genomovars is unknown. The clinical outcome of infection with the two most commonly isolated genomovars (B cenocepacia and B multivorans) was studied at a specialist CF centre between 1982 and 2003.

Methods: The numbers of patients who progressed from initial to chronic infection were assessed. Control groups were created by matching patients with chronic BCC infection by percentage forced expiratory volume in 1 second with patients with Pseudomonas aeruginosa infection. Outcome measures were survival time, deaths from “cepacia syndrome”, rate of decline in spirometry and body mass index (BMI), and treatment requirements.

Results: Forty nine patients had an initial infection with either B multivorans (n = 16) or B cenocepacia (n = 33); 8/16 and 31/33, respectively, developed chronic infection (p < 0.001). Deaths from “cepacia syndrome” occurred in both BCC groups. Patients with B cenocepacia infection had a shorter survival than patients with P aeruginosa infection (p = 0.01). There was no difference in survival between CF patients infected with B multivorans and P aeruginosa. There were no observed differences in changes in spirometry and BMI or treatment requirements between the BCC groups and respective controls.

Conclusion: In CF, the genomovar status of BCC may influence both the likelihood of progression from initial to chronic infection and the overall survival of the patients.

In the 1980s it became recognised that an organism known as Burkholderia cepacia was an opportunistic pathogen for individuals with cystic fibrosis (CF). Pulmonary infection with B cepacia was associated with increased rates of morbidity and mortality. In a proportion of patients infection also caused a fulminating pneumonic illness with high temperatures and respiratory failure sometimes associated with septicemia which became known as “cepacia syndrome”. Furthermore, the emergence and spread of a number of epidemic strains presented cross-infection control problems for CF patients in the community and at CF centres.

Recent studies, however, have shown that organisms presumptively identified as B cepacia by conventional phenotypic tests constitute different genotypic species, each now known as a genomovar of the B cepacia complex (BCC). Although a considerable amount of work has been carried out in taxonomic analysis to define the different species of the BCC, the relevance of this classification to the CF clinician is unknown. The majority of BCC isolates from CF centres belong either to B multivorans (BCC genomovar II) or B cenocepacia (BCC genomovar III). It is recognised that CF patients with BCC infection can have a worse outcome following lung transplantation and this may depend on the genomovar status of the organism. The overall morbidity and mortality for CF patients resulting from infection by different genomovars of the BCC is, however, unknown. We now report the clinical outcome of patients with B multivorans and B cenocepacia infections at a specialist adult CF centre.

Methods

Data were collected by a retrospective review of the case records of all CF patients infected with BCC at the Manchester Adult CF Centre. In order to prevent survivor bias, only patients who had become infected with BCC since referral to the Adult Centre (1982–2003) were included in the study. For the purpose of this study, the date of acquisition of BCC infection was defined as the date the organism was first isolated from sputum samples. BCC infection was classified as transient if at least three consecutive cultures failed to yield the organism over a minimum period of 12 months.

Patients were grouped according to the results of genomovar typing of isolates identified by RecA-PCR analysis. Typing of isolates by pulsed field gel electrophoresis (PFGE) was also performed to assess the clonality of isolates within each group. Cases in which BCC strains have cross-infected CF patients already infected with other BCC have been described. We therefore reviewed previous typing results of patient isolates to see if they had changed their species and strain. For patients with B multivorans infection we looked at the last isolate taken prior to death.

Using a research database, each patient who developed chronic BCC infection was individually matched with another CF patient who had been referred to the adult centre within the same 12 month period and had chronic Pseudomonas aeruginosa infection. Matching was by the percentage predicted forced expiratory volume in 1 second (%FEV1) at the time the BCC species was first isolated. Patients with B cenocepacia infection and patients with B multivorans infection therefore each had their own control groups.

The age, %FEV1, percentage predicted forced vital capacity (%FVC), and body mass index (BMI) of the patients were calculated at acquisition and annually for up to 5 years after the acquisition date. A mean of the available values of a month either side of the acquisition date was taken. For each group of patients the number of deaths and time to death (in months) were recorded. For patients with BCC infection the number of deaths from “cepacia syndrome” was also noted.
Burkholderia cepacia complex in CF

 usando a Kaplan-Meier plot and the groups were compared. The percentage survival at 1 year and 5 years was calculated.

Patients had developed infection with the groups consisting of patients with transient infection: 8/16 and 2/33 with were not included in the present study. Ten patients had a transient infection in age, sex, %FEV1, and %FVC at baseline, although in comparison to their respective controls, and patients with B cepacia infection had a shorter survival time (table 2, fig 1). One patient with B multivorans and two patients with B cepacia infection died of “cepacia syndrome”; the times of death from initial infection were 22, 9, and 22 months, respectively. Three patients with B cepacia infection died within a year of developing infection. With the exception of survival times, there was insufficient clinical follow up data from the three patients, so all three patients and their respective controls were excluded from the analysis of follow up clinical data. All other patients contributed to the data. There were no significant differences observed between either BCC group and their respective controls in annual number of respiratory exacerbations, inpatient days, and intravenous antibiotic treatment days (table 4).

An Analysis of data

Statistical analysis was performed using SPSS statistical package version 9.0 (SPSS Inc, Chicago, Illinois, USA). The two BCC groups were compared with each other for number of patients who progressed from initial to chronic infection and number of deaths from “cepacia syndrome”. Otherwise, the BCC groups were compared with their respective control groups consisting of patients with P aeruginosa infection. The percentage survival at 1 year and 5 years was calculated using a Kaplan-Meier plot and the groups were compared using the log rank test. Other comparisons were assessed by McNemar, Wilcoxon and paired t tests.

RESULTS

Forty nine CF patients had become infected with B multivorans (n = 16) or B cepacia (n = 33) since referral to the Adult Centre. Another patient had chronic infection with a B anthina (BCC genovar VIII) strain and a further six patients had developed infection with B gladioli; these cases were not included in the present study. Ten patients had a transient infection: 8/16 and 2/33 with B multivorans and B cepacia, respectively (p<0.001). Interestingly, the two cases of transient infection with B cepacia involved the notorious epidemic strain known as ET12.

All B multivorans isolates had unique PFGE typing profiles. In contrast, the majority (29/33) of isolates from patients with B cepacia were identified by PFGE as the ET12 strain. None of the patients with B multivorans infection developed superinfection with B cepacia, but one patient with B cepacia infection was found to have acquired a different strain of B cepacia that replaced the original B cepacia strain.

There were no significant differences between the BCC groups and their respective controls with P aeruginosa infection in age, sex, %FEV1, and %FVC at baseline, although patients with B multivorans infection had a lower mean BMI than their controls (table 1). There were more deaths among the patients with B cepacia infection than their respective controls, and patients with B cepacia infection had a shorter survival time (table 2, fig 1). One patient with B multivorans and two patients with B cepacia infection died of “cepacia syndrome”; the times of death from initial infection were 22, 9, and 22 months, respectively. Three patients with B cepacia infection died within a year of developing infection. With the exception of survival times, there was insufficient clinical follow up data from the three patients, so all three patients and their three respective P aeruginosa controls were excluded from the analysis of follow up clinical data. All other patients contributed to the data. There were no significant differences observed between either BCC group and their respective controls in annual number of respiratory exacerbations, inpatient days, and intravenous antibiotic treatment days (table 4).

DISCUSSION

This study examines whether infection with B cepacia and B multivorans respectively affect the clinical outcome of CF patients above that of P aeruginosa, the most prevalent

<p>| Table 1 Baseline demographic data of patients with chronic BCC infection at acquisition and P aeruginosa controls |
|---------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|</p>
<table>
<thead>
<tr>
<th>B cepacia (n = 31)</th>
<th>P aeruginosa (n = 31)</th>
<th>p value</th>
<th>B multivorans (n = 8)</th>
<th>P aeruginosa (n = 8)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>22.0 (4.7)</td>
<td>23.4 (5.2)</td>
<td>0.14</td>
<td>21.8 (4.8)</td>
<td>21.7 (4.1)</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>18/13</td>
<td>14/17</td>
<td>0.45</td>
<td>7/1</td>
<td>6/2</td>
</tr>
<tr>
<td>%FEV1</td>
<td>52.0 (19.6)</td>
<td>51.8 (21.2)</td>
<td>0.90</td>
<td>56.5 (20.2)</td>
<td>53.6 (17.9)</td>
</tr>
<tr>
<td>%FVC</td>
<td>73.1 (19.7)</td>
<td>69.5 (19.6)</td>
<td>0.17</td>
<td>76.9 (20.7)</td>
<td>79.9 (19.7)</td>
</tr>
<tr>
<td>BMI</td>
<td>18.7 (1.8)</td>
<td>19.7 (3.1)</td>
<td>0.10</td>
<td>18.9 (1.3)</td>
<td>20.9 (1.4)</td>
</tr>
</tbody>
</table>

FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; BMI, body mass index.

Results expressed as mean (SD).

<p>| Table 2 Survival of patients with BCC infection and matched controls with P aeruginosa infection |
|---------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|</p>
<table>
<thead>
<tr>
<th>B cepacia (n = 31)</th>
<th>P aeruginosa (n = 31)</th>
<th>p value</th>
<th>B multivorans (n = 8)</th>
<th>P aeruginosa (n = 8)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deaths</td>
<td>19</td>
<td>8</td>
<td>–</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Capacia syndrome</td>
<td>2</td>
<td>–</td>
<td>–</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>1 year survival</td>
<td>80.2%</td>
<td>100%</td>
<td>–</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>5 year survival</td>
<td>66.6%</td>
<td>85.3%</td>
<td>0.01</td>
<td>75.0%</td>
<td>75.0%</td>
</tr>
</tbody>
</table>

www.thoraxjnl.com

Figure 1 Survival of CF patients with chronic B cepacia infection and matched controls with chronic P aeruginosa infection (n = 31 in each group).
pathogen for this group of patients. There was a greater overall number of deaths and significantly shortened survival for patients with *B. cenocepacia* infection in comparison with matched patients with *P. aeruginosa* infection. There was no difference in survival between patients infected with *B. multivorans* and *P. aeruginosa*, although the number of patients was small.

Transient infection with *BCC* has been observed in 5–10% of cases, but the rates for individual genomovars are unclear. In our study the proportion of patients who had a transient infection was significantly greater with *B. multivorans* than *B. cenocepacia* (*p* < 0.001). A recent Canadian study also described transient infection with *B. multivorans* in 10 of 19 patients. Of importance, two patients in our study also demonstrated transient infection with the ET12 strain of *B. cenocepacia*. The possibility of whether BCC infection may be transient is important for CF patients and carers, given the current stigma associated with *BCC* infection and its implications in terms of segregation policies. The UK CF Trust currently recommends a period of at least 1 year with at least three consecutive negative cultures before a patient is considered free of *BCC* infection. In the meantime, the patient must be segregated from all other CF patients.

“Cepacia syndrome” is recognised as an almost untreatable clinical condition. In the present study there were cases of *cepacia* syndrome in association with both *B. cenocepacia* and *B. multivorans*.

Spirometry and nutritional status are known predictors of survival for individuals with CF. The effects of *B. cepacia* infection on lung function and its relationship to the increased mortality associated with the organism for individuals with CF are complex. Mundie et al. found that *B. cepacia* infection caused an accelerated decline in pulmonary function and an increased mortality, although studies by Isles et al. and Frangolias et al. did not find any significant difference in decline in lung function but did demonstrate a survival disadvantage in comparison with non-infected CF patients. In the present study patients with *B. cenocepacia* had a decreased survival but without significant change in spirometry compared with their control group. Mean BMI increased in all patient groups in the present study. This may seem somewhat unusual; however, the increase in BMI over time is a reflection of the overall trend in nutritional status for all CF patients at our centre. There was no difference in weight loss between *B. cepacia* infected and non-infected CF patients in a recent study.

Previous studies have shown an increase in the use of hospital services and treatment requirements for CF patients following *B. cepacia* infection in terms of a significant rise in the number of inpatient days, intravenous antibiotic days, and outpatient visits. In the present study, patients with *B. cenocepacia* infection were found to have a greater number of clinic visits than patients with *P. aeruginosa* infection. However, the *BCC* groups did not significantly differ in the number of infective exacerbations, requirement for inpatient treatment, and intravenous antibiotics in comparison with their control groups. The factors influencing the clinical course of a patient following acquisition of *BCC* infection are clearly complex and probably influenced by multiple factors, including host response to the pathogen. As evidence for the importance of host factors, an early study showed that patients infected with the same ET12 strain of *B. cenocepacia* displayed marked differences in their clinical course.

The majority of *BCC* infections at the Manchester Adult CF Centre are with *B. multivorans* (30.6%) or *B. cenocepacia* (67.3%). While each patient’s *B. multivorans* isolate is a unique strain, the majority (87.9%) of *B. cenocepacia* isolates belong to a single epidemic strain (the ET12 strain). Most highly transmissible strains of *BCC* are *B. cepacia*, although *B. multivorans* strains have been associated with epidemic spread. The introduction of strict segregation policies over the last decade will probably influence the proportion of new infections belonging to the different genomovars.

Mahenthiralingam et al. reported a higher mortality among CF patients with *B. cepacia* in Vancouver than patients

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Annual changes in spirometric parameters and body mass index (BMI) for CF patients with BCC infection and matched controls with <em>P. aeruginosa</em> infection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><em>B. cenocepacia</em></td>
</tr>
<tr>
<td>---------</td>
<td>-----------------</td>
</tr>
<tr>
<td>%FEV1</td>
<td>–2.7% (–47.1 to +13.0)</td>
</tr>
<tr>
<td>%FVC</td>
<td>–1.7% (–38.7 to +13)</td>
</tr>
<tr>
<td>BMI</td>
<td>0.7 (1.5)</td>
</tr>
</tbody>
</table>

Results expressed as mean (SD) or median (range) and estimated mean or median differences between the groups (*P. aeruginosa* v *B. cenocepacia* or *P. aeruginosa* v *B multivorans*) and 95% confidence intervals or ranges.

<table>
<thead>
<tr>
<th>Table 4</th>
<th>Annual treatment requirements between CF patients with BCC infection and matched controls with <em>P. aeruginosa</em> infection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><em>B. cenocepacia</em></td>
</tr>
<tr>
<td>---------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Exacerbations</td>
<td>5.5 (2.4)</td>
</tr>
<tr>
<td>Clinic visits</td>
<td>12.6 (5.3)</td>
</tr>
<tr>
<td>Inpatient days</td>
<td>27.8 (0 to 91.4)</td>
</tr>
<tr>
<td>Intravenous antibiotics</td>
<td>5.2 (0 to 147.0)</td>
</tr>
</tbody>
</table>

Results expressed as mean (SD) or median (range) and estimated mean or median differences between the groups (*P. aeruginosa* v *B. cenocepacia* or *P. aeruginosa* v *B multivorans*) and 95% confidence intervals or ranges.
with *B multivorans*.\(^{15}\) However, there were significant age differences between the two groups. The present study has compared patients with *Burkholderia* species with matched controls with *P aeruginosa* using %FEV\(_1\). It should be acknowledged that, as the survival analysis does not allow for the matching, the effect estimates may be conservative.

A limitation of this study is the small numbers of patients, particularly those with *B multivorans* infection. A further limitation is that the data and conclusions have been heavily influenced by the presence of a single highly transmissible *B cenocepacia* strain. In the study by Mahenthiralingam et al all the patients with *B cenocepacia* also had transmissible strains. The only other published studies of outcome of *BCC* infection in CF have studied patients following transplantation.\(^{12,11}\) Chapparo et al\(^ {11}\) found a poorer outcome for CF patients with *B cepacia* infection following lung transplantation, and De Soyza et al\(^ {12}\) reported a worse outcome following transplantation with *B cepacia* than with other *BCC*. Finally, Aris et al\(^ {11}\) found that decreased survival after transplantation was linked to genomovar status irrespective of strain type, with a worse outcome for CF patients with *B cenocepacia* infection, all of whom harboured unique genotypic strains. Further studies of the clinical effects of *BCC* infection in CF patients are required.

Replacement of existing *BCC* by the *B cepacia* strain ET12 has been reported.\(^ {15,16}\) Our study reviewed the clinical outcome between groups of patients with infection by strains that differ in their genomovar status. None of the patients in the present study are known to have died as a result of cross-infection by a different genovar of *BCC*, although one patient did acquire a different strain but of the same genovar. Current UK guidelines advocate a policy of segregation of CF patients with *BCC* infection irrespective of genovar status.\(^ {17}\)

This study has shown that the rate of transient infection and clinical outcome, including patient survival, for *BCC* infection in CF may be influenced by genovar status, and perhaps by individual strains within genomovars.

**Authors’ affiliations**

A M Jones, M E Dodd, A K Webb, Manchester Adult Cystic Fibrosis Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester M23 9LT, UK  
J R W Govan, V Barcus, C J Doherty, Medical Microbiology, University of Edinburgh, Edinburgh EH8 9AG, UK  
J Morris, Department of Medical Statistics, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester M23 9LT, UK  
This study was unfunded.

**References**


**Burkholderia cenocepacia and Burkholderia multivorans**: influence on survival in cystic fibrosis

A M Jones, M E Dodd, J R W Govan, V Barcus, C J Doherty, J Morris and A K Webb

*Thorax* 2004 59: 948-951
doi: 10.1136/thx.2003.017210

Updated information and services can be found at:
http://thorax.bmj.com/content/59/11/948

These include:

**References**

This article cites 18 articles, 8 of which you can access for free at:
http://thorax.bmj.com/content/59/11/948#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Cystic fibrosis (525)
- Airway biology (1100)
- Lung function (773)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/